Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis

OBJECTIVES: We aimed to assess the expression of the CCL24 chemokine in systemic sclerosis (SSc) and to evaluate the possible pathogenic implications of the CCL24/CCR3 axis using both in vitro and in vivo models. We further investigated the efficacy of an anti-CCL24 monoclonal antibody (mAb), CM-101...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ann Rheum Dis
Päätekijät: Mor, Adi, Segal Salto, Michal, Katav, Avi, Barashi, Neta, Edelshtein, Victoria, Manetti, Mirko, Levi, Yair, George, Jacob, Matucci-Cerinic, Marco
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2019
Aiheet:
Systemic Sclerosis
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6788878/
https://ncbi.nlm.nih.gov/pubmed/31129606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2019-215119
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia